Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013

Mary Gleeson; Eliza A. Hawkes; Clare Peckitt; Andrew Wotherspoon; Ayoma Attygalle; Bhupinder Sharma; Yong Du; Mark Ethell; Mike Potter; Claire Dearden; Alan Horwich; Ian Chau; David Cunningham

doi:10.1080/10428194.2016.1265114

Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013

Mary Gleeson, Eliza A. Hawkes, Clare Peckitt, Andrew Wotherspoon, Ayoma Attygalle, Bhupinder Sharma, Yong Du, Mark Ethell, Mike Potter, Claire Dearden, Alan Horwich, Ian Chau, David Cunningham

Research output: Contribution to journal › Article › Research › peer-review

18 Citations (Scopus)

Abstract

Survival for transformed follicular lymphoma (tFL) has improved in the rituximab era and the need for upfront stem cell transplantation (SCT) is unclear. We evaluated the outcomes for all patients treated with first-line chemotherapy for histologically-proven tFL at our institution from 2003–2013 (n = 87). The majority of patients (89.7%) did not receive a SCT as part of first-line management. With a median follow-up of 7.8 years the 5-year overall survival (OS) for all patients was 61.7%. Patients treated with R-CHOP without upfront SCT (n = 55/87) had a 5-year OS of 64.3%. In a Cox regression analysis of the entire cohort (n = 87) International Prognostic Index (IPI) risk group and presence of B symptoms at transformation were independently associated with OS in multivariate analysis (MVA). Our analysis confirms the improved survival of tFL in the rituximab era even in the absence of upfront SCT consolidation.

Original language	English
Pages (from-to)	1805-1813
Number of pages	9
Journal	Leukemia and Lymphoma
Volume	58
Issue number	8
DOIs	https://doi.org/10.1080/10428194.2016.1265114
Publication status	Published - 3 Aug 2017
Externally published	Yes

Keywords

Follicular lymphoma
high-grade transformation
rituximab era
stem-cell transplantation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10428194.2016.1265114

Cite this

Gleeson, M., Hawkes, E. A., Peckitt, C., Wotherspoon, A., Attygalle, A., Sharma, B., Du, Y., Ethell, M., Potter, M., Dearden, C., Horwich, A., Chau, I., & Cunningham, D. (2017). Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013. Leukemia and Lymphoma, 58(8), 1805-1813. https://doi.org/10.1080/10428194.2016.1265114

@article{3cbcdee8d2974ffe93c44a09dccf03d2,

title = "Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013",

abstract = "Survival for transformed follicular lymphoma (tFL) has improved in the rituximab era and the need for upfront stem cell transplantation (SCT) is unclear. We evaluated the outcomes for all patients treated with first-line chemotherapy for histologically-proven tFL at our institution from 2003–2013 (n = 87). The majority of patients (89.7%) did not receive a SCT as part of first-line management. With a median follow-up of 7.8 years the 5-year overall survival (OS) for all patients was 61.7%. Patients treated with R-CHOP without upfront SCT (n = 55/87) had a 5-year OS of 64.3%. In a Cox regression analysis of the entire cohort (n = 87) International Prognostic Index (IPI) risk group and presence of B symptoms at transformation were independently associated with OS in multivariate analysis (MVA). Our analysis confirms the improved survival of tFL in the rituximab era even in the absence of upfront SCT consolidation.",

keywords = "Follicular lymphoma, high-grade transformation, rituximab era, stem-cell transplantation",

author = "Mary Gleeson and Hawkes, {Eliza A.} and Clare Peckitt and Andrew Wotherspoon and Ayoma Attygalle and Bhupinder Sharma and Yong Du and Mark Ethell and Mike Potter and Claire Dearden and Alan Horwich and Ian Chau and David Cunningham",

year = "2017",

month = aug,

day = "3",

doi = "10.1080/10428194.2016.1265114",

language = "English",

volume = "58",

pages = "1805--1813",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor & Francis",

number = "8",

}

Gleeson, M, Hawkes, EA, Peckitt, C, Wotherspoon, A, Attygalle, A, Sharma, B, Du, Y, Ethell, M, Potter, M, Dearden, C, Horwich, A, Chau, I & Cunningham, D 2017, 'Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013', Leukemia and Lymphoma, vol. 58, no. 8, pp. 1805-1813. https://doi.org/10.1080/10428194.2016.1265114

TY - JOUR

T1 - Outcomes for transformed follicular lymphoma in the rituximab era

T2 - the Royal Marsden experience 2003–2013

AU - Gleeson, Mary

AU - Hawkes, Eliza A.

AU - Peckitt, Clare

AU - Wotherspoon, Andrew

AU - Attygalle, Ayoma

AU - Sharma, Bhupinder

AU - Du, Yong

AU - Ethell, Mark

AU - Potter, Mike

AU - Dearden, Claire

AU - Horwich, Alan

AU - Chau, Ian

AU - Cunningham, David

PY - 2017/8/3

Y1 - 2017/8/3

N2 - Survival for transformed follicular lymphoma (tFL) has improved in the rituximab era and the need for upfront stem cell transplantation (SCT) is unclear. We evaluated the outcomes for all patients treated with first-line chemotherapy for histologically-proven tFL at our institution from 2003–2013 (n = 87). The majority of patients (89.7%) did not receive a SCT as part of first-line management. With a median follow-up of 7.8 years the 5-year overall survival (OS) for all patients was 61.7%. Patients treated with R-CHOP without upfront SCT (n = 55/87) had a 5-year OS of 64.3%. In a Cox regression analysis of the entire cohort (n = 87) International Prognostic Index (IPI) risk group and presence of B symptoms at transformation were independently associated with OS in multivariate analysis (MVA). Our analysis confirms the improved survival of tFL in the rituximab era even in the absence of upfront SCT consolidation.

AB - Survival for transformed follicular lymphoma (tFL) has improved in the rituximab era and the need for upfront stem cell transplantation (SCT) is unclear. We evaluated the outcomes for all patients treated with first-line chemotherapy for histologically-proven tFL at our institution from 2003–2013 (n = 87). The majority of patients (89.7%) did not receive a SCT as part of first-line management. With a median follow-up of 7.8 years the 5-year overall survival (OS) for all patients was 61.7%. Patients treated with R-CHOP without upfront SCT (n = 55/87) had a 5-year OS of 64.3%. In a Cox regression analysis of the entire cohort (n = 87) International Prognostic Index (IPI) risk group and presence of B symptoms at transformation were independently associated with OS in multivariate analysis (MVA). Our analysis confirms the improved survival of tFL in the rituximab era even in the absence of upfront SCT consolidation.

KW - Follicular lymphoma

KW - high-grade transformation

KW - rituximab era

KW - stem-cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=85004154165&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1265114

DO - 10.1080/10428194.2016.1265114

M3 - Article

AN - SCOPUS:85004154165

SN - 1042-8194

VL - 58

SP - 1805

EP - 1813

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 8

ER -

Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this